A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment

Publisher: Blackwell Publishing

E-ISSN: 1097-0142|121|16|2749-2756

ISSN: 0008-543X

Source: Cancer, Vol.121, Iss.16, 2015-08, pp. : 2749-2756

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content